Abstract
Introduction: Gan-jiang-ling-zhu (GJLZ) decoction is a classical traditional Chinese medicine prescription used for chronic digestive diseases, including nonalcoholic fatty liver disease. However, its efficacy and mechanism in treating nonalcoholic steatohepatitis (NASH) remain unelucidated. Methods: NASH was induced in mice, followed by treatment with GJLZ decoction. Evaluation included histological staining (H&E, Oil Red O), triglyceride analysis, gut microbiota profiling, and metabolomics. Results: GJLZ treatment significantly improved hepatic steatosis and remodeled gut flora and metabolites, specifically reducing 12-tridecenoic acid. This metabolite was found to aggravate steatosis by promoting ACC expression and inhibiting CPT1A expression. Conclusion: GJLZ decoction effectively reduces 12-tridecenoic acid levels and improves steatosis by modulating the ACC-CPT1A axis.
Introduction
Nonalcoholic steatohepatitis (NASH) represents an advanced stage of fatty liver disease characterized by inflammation and hepatocellular damage. As a significant global health burden, NASH can progress to cirrhosis or hepatocellular carcinoma, yet pharmacological options remain limited. The "gut-liver axis"—the bidirectional communication between the gastrointestinal tract and the liver—is a critical factor in NASH pathogenesis. While Traditional Chinese Medicine (TCM) formulas like Gan-jiang-ling-zhu (GJLZ) have shown clinical efficacy in treating digestive disorders, the precise molecular mechanisms involving gut flora and microbial metabolites have remained a "black box." This study investigates how GJLZ interacts with the gut-liver axis to treat NASH.
Methods
The researchers utilized a multi-disciplinary approach to investigate GJLZ's effects:
- Animal Models: NASH was induced in C57BL/6J mice using a methionine- and choline-deficient (MCD) diet. Mice were administered low (GJLZ-L) and standard (GJLZ-S) doses of the decoction.
- Microbiome and Metabolomics: 16S rDNA sequencing was performed to profile gut microbial communities (NCBI BioProject: PRJNA1148162), while targeted metabolomics identified changes in fecal metabolites. A library of 48 active ingredients in the GJLZ decoction was verified using UPLC-QTOF/MS.
- Cellular and Molecular Analysis: Findings were validated in vitro using AML12 and HepG2 liver cell lines and primary hepatocytes. Key metabolic enzymes, Acetyl-CoA carboxylase (ACC) and Carnitine palmitoyltransferase 1A (CPT1A), were analyzed via Western blotting and immunofluorescence to assess fatty acid synthesis and oxidation.
Results
GJLZ Ameliorates Hepatic Steatosis and Liver Injury
GJLZ treatment demonstrated significant hepatoprotective effects. In the MCD-induced NASH model, GJLZ administration led to a reduction in the liver weight-to-body weight ratio and significantly lowered serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are primary markers of liver damage. Histological assessments via H&E and Oil Red O staining revealed a dramatic decrease in lipid accumulation and lower NAFLD Activity Scores (NAS) in the GJLZ-treated groups compared to the untreated MCD group.
Identification of 12-Tridecenoic Acid as a Key Pathogenic Metabolite
A central finding of the study was the identification of 12-tridecenoic acid as a microbial metabolite that drives hepatic steatosis. GJLZ treatment effectively remodeled the gut microbiota, reducing the abundance of pro-inflammatory genera such as Desulfovibrio and Bilophila, and significantly lowered the concentration of 12-tridecenoic acid in the gut.
Modulation of the ACC-CPT1A Metabolic Axis
The study elucidated that 12-tridecenoic acid acts as a metabolic disruptor by upregulating ACC (promoting fat synthesis) and inhibiting CPT1A (decreasing fat burning). By reducing 12-tridecenoic acid levels, GJLZ decoction inhibits ACC activity and promotes CPT1A expression, thereby restoring the balance of lipid metabolism in the liver. Additionally, GJLZ was found to support the intestinal barrier by promoting the expression of tight junction proteins like ZO-1 and occludin, potentially preventing the translocation of harmful metabolites.
Conclusion
This research demonstrates that the Gan-jiang-ling-zhu decoction effectively treats NASH by modulating the gut-liver axis. Specifically, it reduces the levels of the harmful microbial metabolite 12-tridecenoic acid, which otherwise aggravates steatosis through the ACC-CPT1A pathway. While these results are promising, the authors note that the MCD diet model does not perfectly replicate human obesity-related NASH. Future research is needed to identify the specific bacterial species responsible for 12-tridecenoic acid production and to validate these findings in human clinical trials.
Summary updated